Diffuse Midline Glioma or Diffuse Intrinsic Pontine GliomaPhase 1NCT07664176
NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors
A Phase 1 study testing NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason and Nivolumab in people with Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma and High Grade Gliomas, run by Children's National Research Institute at 1 site in United States.
Trial summary
This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for progressive and relapsed diffuse midline glioma (DMG) and other progressive and relapsed high-grade brain tumors. Read more about this study
- Who is it for?
- Ages 3 to 25 years
- Conditions the study is for
- Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent
- What is being tested?
- NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason and Nivolumab
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2026to Dec 2030
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Age ≥ 3 and ≤ 25 years.
- Diagnosis of brainstem DMG/DIPG or any high-grade brain tumor.
- Group A: Relapsed or progressive brainstem DMG.
- Group B: Relapsed or progressive high-grade intracranial brain tumor requiring surgical resection.
- Lansky/Karnofsky rating ≥ 60.
- Patients must have received at least one line of prior therapy upfront for their disease.
Show all 24Show fewer
- At least four weeks from radiation therapy, prior immunotherapy, or monoclonal antibody therapy.
- At least 2 weeks from prior myelosuppressive chemotherapy and post nadir meeting organ function criteria.
- At least 1 week or 5 half-lives (whichever is longer) from last targeted therapy.
- If on steroids, stable or decreasing dose for at least 7 days prior to study entry and ≤ 0.4 mg/m2/day of dexamethasone or equivalent.
- Stable or improving neurological status for 7 days prior to study entry.
- Organ function:
- Absolute Neutrophil Count (ANC) ≥750/μL.
- Absolute Lymphocyte Count (ALC) >500/μL.
- Platelets ≥75K, unsupported.
- Coagulation studies: PT and PTT <1.5 ULN and INR (<1.5).
- Bilirubin ≤1.5x upper limit of normal (ULN).
- AST/ALT ≤5x ULN.
- Serum creatinine within normal limits for age.
- Pulse oximetry >93% on room air.
- Ejection Fraction (EF) above institutional lower limit of normal (LLN).
- For females of childbearing potential (FOCBP): negative pregnancy test within 7 days of study entry.
- Patients of childbearing or child-fathering potential must agree to use contraceptive measures for at least 5 months following nivolumab infusion.
- Patient or parent/guardian capable of providing informed consent.
Who cannot join
- Symptoms and signs of increased intracranial pressure.
- Patients with metallic ventricular peritoneal shunts. Subjects with nonmetallic VP shunts or similar will have a technical evaluation of the screening non-contrast CT scan of the head. During the mapping of the target area, if the technical NaviFUS specialist determines that the patient cannot be treated within the safety limits of the system, the patient will not be eligible and will be considered a screen failure.
- Tumor presenting with the following imaging characteristics:
- Evidence of uncal herniation.
- Edema and/or mass effect that causes hydrocephalus.
- Significant areas of necrosis within the tumor that the neurosurgeon feels cannot be avoided during the ultrasound sonication.
Show all 22Show fewer
- Evidence of a significant new hemorrhage. Area of microhemorrhage (defined as less than 5 mm in diameter) in the treatment area can be acceptable but requires the review of the neurosurgeon.
- Containing calcifications in the focused ultrasound sonication beam path and system tools cannot tailor the treatment around these calcification spots.
- Patients who are deemed to have overly bulky tumor by the PI of the study.
- The sonication pathway to the tumor involves:
- More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp.
- Clips, or other non-MRI compatible metallic implanted objects in the skull or the brain, except for shunts.
- Patients receiving anti-coagulant therapy, or medications known to increase risk of hemorrhage, (e.g., ASA, non-steroidal anti-inflammatory drugs [NSAIDs], statins). There is no required washout for eligibility assessment, but patients should be off agents for at least 3 days at the time of procedure or until 5 half-lives of the agent, whichever is longer.
- History of a bleeding disorder, coagulopathy or with a history of clinically significant spontaneous tumor hemorrhage.
- Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular malformation, cerebral aneurysm, or vasculitis.
- Immunosuppression (corticosteroids to prevent/treat brain edema are permitted).
- Patients with uncontrolled HIV.
- Active seizure disorder or epilepsy (clinically significant seizures despite medical treatment) within four weeks prior to first cycle/NaviFUS BBBO procedure captured by history.
- Known sensitivity to gadolinium-based contrast agents.
- Known sensitivity to Lumason® ultrasound contrast agent or known hypersensitivity to sulphur hexafluoride microsphere or its components, e.g., polyethylene glycol.
- Patients unable to fit comfortably into the MRI scanner (generally >250 lbs.).
- Evidence of cranial or systemic infection.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Children's National Hospital
Washington D.C., District of Columbia, 20010
Elizabeth Paronett, 202-476-5551, eparonett@childrensnational.org
Julia Mascia, 202-476-2907, jmascia@childrensnational.org
About this study
Official title: A Safety and Feasibility Study of NeuroNavigation-Guided Low Intensity Focused Ultrasound With Microbubbles to Enhance Nivolumab Delivery for the Treatment of Relapsed and Progressive Diffuse Midline Glioma and Other High Grade Brain Tumors
This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for progressive and relapsed diffuse midline glioma (DMG) and other progressive and relapsed high-grade brain tumors. This study combines intravenous nivolumab therapy infused following transient blood-brain barrier opening (BBBO) using low-intensity focused ultrasound with microbubble (LIFU-MB) treatment using NeuroNavigation-Guided Focused Ultrasound (NgFUS).
There are two groups in this study:
Read more
- Group A: Patients with relapsed or progressive diffuse midline glioma in the brainstem
- Group B: Patients with relapsed or progressive high grade brain tumor that clinically require surgical resection
The primary outcome is to evaluate the safety and feasibility of 3 cycles of nivolumab with BBB disruption using NgFUS with microbubbles in pediatric patients with progressive or relapsed brainstem DMG or with high grade brain tumors after surgery. Secondary outcomes include preliminary efficacy and immunological effects.
- Conditions
- Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent, Ependymoma Recurrent, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, Brain Tumor Recurrent
- Being tested
- NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason, Nivolumab
- Keywords
- Focused Ultrasound, Pediatrics, Diffuse Midline Glioma, DMG, Diffuse Intrinsic Pontine Glioma, DIPG, High Grade Glioma, HGG, Nivolumab
- Medical subject headings
- Diffuse Intrinsic Pontine Glioma, Rhabdoid Tumor, Brain Neoplasms, Glioma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NeuroNavigation-Guided Focused Ultrasound (NgFUS)Device
NeuroNavigation-Guided Focused Ultrasound, every 2 or 4 weeks for 3 cycles of 28 days
LumasonDrug
Lumason is a sulfur hexafluoride microsphere ultrasound contrast agent which will be used as a mechanical resonator. Lumason will be given in combination with NgFUS every 2 or 4 weeks for 3 cycles of 28 days.
NivolumabDrug
Nivolumab is a monoclonal antibody targeting the immune checkpoint axis PD-1/PD-L1. Nivolumab will be given prior to NgFUS with microbubbles (Lumason) every 2 or 4 weeks for 3 cycles of 28 days.
| Study group | Role | What they receive |
|---|---|---|
| Group A: Patients with relapsed or progressive diffuse midline glioma in the brainstem | Experimental | Patients with relapsed or progressive diffuse midline glioma in the brainstem, receiving nivolumab with NgFUS either every 2 weeks or every 4 weeks. Receives: Device: NeuroNavigation-Guided Focused Ultrasound (NgFUS); Drug: Lumason; Drug: Nivolumab |
| Group B: Patients with relapsed or progressive high grade brain tumors requiring surgical resection | Experimental | Patients with relapsed or progressive high grade brain tumors that clinically require surgical resection, receiving one dose of NgFUS prior to surgery, and nivolumab with NgFUS every 4 weeks following recovery from surgery. Receives: Device: NeuroNavigation-Guided Focused Ultrasound (NgFUS); Drug: Lumason; Drug: Nivolumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of dose limiting toxicities (DLT) as assessed by CTCAE v6.0.
Safety will be evaluated by the incidence of DLTs. DLT is defined as toxicities which are at least possibly related to treatment and meeting protocol-specified criteria for grade, duration, severity, and/or delay of subsequent treatment cycles. If the overall toxicity rate exceeds protocol-specified criteria, enrollment will be halted and the study will be amended to modify the treatment plan.
Measured: First treatment through 28 days post-first treatment.
Percentage of patients completing at least two cycles of planned therapy
Treatment will be determined feasible if at least 80% of enrolled patients complete at least 2 cycles of planned therapy. Feasibility will be assessed separately for each cohort.
Measured: Enrollment through end of Cycle 2 (each cycle is 28 days).
Secondary outcomes (3)
Overall response assessment per RAPNO.
Overall response assessment: complete response (CR), partial response (PR), minor response (MR), stable disease (SD), or progressive disease (PD) following treatment, will be assessed based on the Response Assessment in Pediatric Neuro-Oncology (RAPNO) scale.
Measured: From screening through 1 year post-final treatment.
Progression-free survival (PFS)
PFS is defined as the interval of time between the date of protocol treatment initiation and the earliest date of documentation of progressive disease, or second malignancy or death (for any reason) for patients who fail, or to date of last contact or initiation of other therapy for patients who remain at risk of failure.
Measured: From enrollment through up to 2 years post-final treatment.
Overall survival (OS)
OS post nivolumab infusion will be analyzed by the Kaplan-Meier method.
Measured: From enrollment through up to 2 years post-final treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2026
- Study startSep 2026 (estimated)
- Primary completionDec 2030 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diffuse Midline Glioma or Diffuse Intrinsic Pontine GliomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Children's National Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07664176
- Sponsor's protocol ID
- STUDY00001735
- Status last verified
- Sep 2026
- First submitted
- 20 May 2026
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- Yes
- Individual data sharing
- No